公司資料
Bone Biologics 股價、新聞與催化劑
- 股票代碼:
- BBLG
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.47 USD (-3.77%)
收盤價
最後更新: 2026年10月8日
2.28M USD
市值
股價為何變動
截至 2026年10月8日，BBLG 下跌 3.77%，收於 $0.4691。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
Orthobiologic Product Developer
Bone Biologics develops biologic products intended to improve bone formation in spinal fusion. Its lead candidate combines a recombinant growth factor with a commonly used bone-graft material.
NB1 Bone Graft Candidate
NB1 combines recombinant human NELL-1 protein with demineralized bone matrix. NELL-1 is intended to promote targeted bone formation while the matrix provides a scaffold for new tissue growth.
Lumbar Fusion Pilot Study
The first-in-human clinical study is evaluating NB1 in patients undergoing transforaminal lumbar interbody fusion for degenerative disc disease. The trial compares the product's safety and fusion performance with standard grafting approaches.
Pivotal Development Path
The pilot design was reviewed with the FDA and is intended to inform a later U.S. pivotal study. Clinical evidence from Australia will help determine sample size, endpoints, and the broader regulatory strategy.
Manufacturing and Product Stability
Bone Biologics is developing manufacturing, quality, and storage processes for recombinant NELL-1. Extending validated shelf life improves the practicality of supplying clinical sites and future commercial customers.
未來催化劑
- Completion of enrollment in the first-in-human NB1 pilot study by the end of 2026.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。